SCHEMBL20239259

SCHEMBL20239259

CN(C)c1nc(CNc2ncc(Cl)cn2)cc(Oc2ccc(NS(C)(=O)=O)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.49
PGR P06401 1/20 0.38
PTK2 Q05397 1/20 0.37
LTA4H P09960 1/20 0.37
KCNH2 Q12809 3/20 0.37
GRIN1 Q05586 3/20 0.37
GRIN2B Q13224 3/20 0.37
MET P08581 1/20 0.36
CACNA1F O60840 1/20 0.35
CHRM2 P08172 1/20 0.35
ACHE P22303 1/20 0.35
AGTR1 P30556 1/20 0.35
DRD3 P35462 1/20 0.35
CACNA1D Q01668 1/20 0.35
CACNA1S Q13698 1/20 0.35
CACNA1C Q13936 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SLC6A4 P31645 2/20 0.35
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239208 0.87 DGAT2 (0.53) DGAT2PGRPTK2LTA4HKCNH2
SCHEMBL20239246 0.86 DGAT2 (0.50) DGAT2PGRPTK2LTA4HKCNH2
SCHEMBL20239257 0.85 DGAT2 (0.67) DGAT2METRAB9ASMN1; SMN2KDM4E
SCHEMBL20239200 0.80 DGAT2 (0.76) DGAT2LTA4HKCNH2GRIN1GRIN2B
SCHEMBL20239364 0.79 DGAT2 (0.62) DGAT2PTK2METSMN1; SMN2MAPT
SCHEMBL20239321 0.78 DGAT2 (0.46) DGAT2PGRPTK2LTA4HKCNH2
SCHEMBL20239141 0.76 DGAT2 (0.42) DGAT2PGRPTK2LTA4HKCNH2
SCHEMBL20239338 0.76 SMN1; SMN2 (0.46) DGAT2PGRPTK2LTA4HKCNH2
SCHEMBL20239226 0.73 DGAT2 (0.53) DGAT2KCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL20239204 0.72 DGAT2 (0.69) DGAT2METNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885PGR 2121/4885PTK2 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.